Evolent Health, Inc. (NYSE:EVH) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lowered its stake in Evolent Health, Inc. (NYSE:EVHFree Report) by 90.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,514 shares of the technology company’s stock after selling 104,781 shares during the period. Principal Financial Group Inc.’s holdings in Evolent Health were worth $314,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in EVH. ICA Group Wealth Management LLC bought a new position in Evolent Health in the 4th quarter worth $32,000. Captrust Financial Advisors boosted its stake in Evolent Health by 254.4% during the second quarter. Captrust Financial Advisors now owns 1,758 shares of the technology company’s stock worth $54,000 after buying an additional 1,262 shares in the last quarter. West Tower Group LLC bought a new stake in Evolent Health in the 2nd quarter valued at $124,000. Nisa Investment Advisors LLC raised its stake in shares of Evolent Health by 389.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,035 shares of the technology company’s stock valued at $137,000 after buying an additional 4,006 shares in the last quarter. Finally, Strs Ohio lifted its stake in Evolent Health by 256.3% during the second quarter. Strs Ohio now owns 5,700 shares of the technology company’s stock worth $172,000 after purchasing an additional 4,100 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. StockNews.com raised Evolent Health to a “sell” rating in a report on Monday, October 16th. Wedbush reissued an “outperform” rating on shares of Evolent Health in a report on Thursday, November 16th. Truist Financial lowered their target price on Evolent Health from $36.00 to $34.00 and set a “hold” rating for the company in a research note on Tuesday, November 14th. Royal Bank of Canada decreased their price target on Evolent Health from $44.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday, November 28th. Finally, Barclays assumed coverage on Evolent Health in a report on Wednesday, January 3rd. They set an “overweight” rating and a $39.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.25.

Check Out Our Latest Research Report on EVH

Insiders Place Their Bets

In other news, President Daniel Joseph Mccarthy sold 11,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $30.00, for a total transaction of $330,000.00. Following the sale, the president now owns 198,333 shares of the company’s stock, valued at $5,949,990. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Evolent Health news, President Daniel Joseph Mccarthy sold 11,000 shares of Evolent Health stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $30.00, for a total value of $330,000.00. Following the sale, the president now owns 198,333 shares of the company’s stock, valued at approximately $5,949,990. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Seth Blackley sold 141,000 shares of the stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $26.54, for a total value of $3,742,140.00. Following the transaction, the chief executive officer now owns 637,645 shares of the company’s stock, valued at $16,923,098.30. The disclosure for this sale can be found here. Corporate insiders own 3.30% of the company’s stock.

Evolent Health Price Performance

Shares of EVH stock opened at $31.46 on Tuesday. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.55. Evolent Health, Inc. has a 12-month low of $23.33 and a 12-month high of $36.70. The firm has a fifty day moving average of $30.83 and a 200-day moving average of $28.49. The firm has a market capitalization of $3.62 billion, a price-to-earnings ratio of -30.84 and a beta of 1.49.

Evolent Health Profile

(Free Report)

Evolent Health, Inc, a healthcare company, through its subsidiary, Evolent Health LLC, offers clinical and administrative solutions to payers and providers in the United States. The company operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.

Further Reading

Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health, Inc. (NYSE:EVHFree Report).

Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.